CM
GLUE icon

Caption Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Caption Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-108,400
Closed -$612K – 1382
2023
Q4 		$612K Sell
108,400
-12,600
-10% -$49.4K 0.01% 911
2023
Q3 		$580K Buy
+121,000
New +$779K 0.01% 903

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caption Management's GLUE Position: Q1 2024 in Review

Caption Management sold out of Monte Rosa Therapeutics (GLUE) in Q1 2024, closing a stake of 90,690 shares — an estimated $512K sold.

Caption Management first reported a position in GLUE in Q4 2023 and held it in 1 quarter. The position peaked at $512K in Q4 2023. 68 funds tracked by Wall St. Rank hold GLUE as of Q1 2024.

  • Caption Management reported no remaining Monte Rosa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Caption Management sold 90,690 Monte Rosa Therapeutics shares in Q1 2024, an estimated $512K.
  • Caption Management first reported a position in Monte Rosa Therapeutics in Q4 2023 and held it in 1 quarter.
  • Caption Management's Monte Rosa Therapeutics position peaked at $512K in Q4 2023.
  • 68 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.